Ceapro's Research Scientist, Bernhard Seifried, Ph.D., Honored with Scientific Achievement & Innovation Award from BioAlberta
Ceapro's PGX Technology enables production of pharmaceutical grade Beta Glucan
EDMONTON, ALBERTA -- (Marketwired) -- 11/26/14 -- Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Bernhard Seifried, Ph.D., Senior Research Scientist at the Company, was recognized as the recipient of the Achievement Award for Scientific Achievement & Innovation at the BioAlberta 15th Annual General Meeting and Awards Gala in Calgary, Canada on November 25. The BioAlberta Scientific Achievement & Innovation award honors scientists and entrepreneurs who have demonstrated leadership and made significant, extensive and tangible contributions to the Alberta and Canadian life science community.
Dr. Seifried is the co-inventor of the novel platform processing technology called Pressurized Gas eXpanded Liquid Technology (PGX). PGX is a unique and disruptive technology with several key advantages over conventional drying and purification technologies that can be used to process biopolymers into high-value nano-sized polymer structures and novel bio-nanocomposites. PGX is ideally suited for processing challenging high-molecular weight water soluble bio-polymers and has the ability to make ultra-light, highly porous polymer structures on a continuous basis which is not possible using today's conventional technologies.
Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro, commented, "We are excited Dr. Seifried has been recognized for this prestigious award. Dr. Seifried's strong scientific acumen will continue to prove to be very important to Ceapro as we leverage his significant contributions in the near-and long-term. Specifically, Ceapro's PGX technology platform will enable the strategic expansion of our business model into highly attractive, well established and growing sectors."
"Amongst a plethora of potential applications, Ceapro has used PGX to produce a high purity dry oat beta glucan that can be developed to act as a delivery system for cosmetic and healthcare markets as well as a systemic active ingredient with contemplated health benefits such as cholesterol reduction," Mr. Gagnon added.
Dr. Seifried earned his Ph.D. in Food and Bioresource Engineering from the University of Alberta where he completed his doctoral project work under Professor Feral Temelli, Ph.D. He then joined Ceapro in 2010 where he successfully designed all the equipment and modifications required to scale-up PGX at a level that will enable commercial applications.
Dr. Seifried is an expert in supercritical fluids and high pressure processing and is a first-author or co-author of numerous research articles published in notable scientific peer-reviewed journals. He received an undergraduate degree in Chemical Engineering from Technische Universität Graz in Austria.
BioAlberta has been the central voice and organizing hub for the life sciences industry in Alberta since 1999 and actively driving the vision of: "A thriving and globally competitive life sciences industry that fuels key sectors of Alberta's economy." BioAlberta is a private, not-for-profit industry association representing more than 140 members of Alberta's steadily increasing life science industry's producers, users and supporters in the province. These member companies operate in the specialized sectors such as health biotechnology and pharmaceuticals; medical technology and devices; agricultural biotechnology; natural health products and nutraceuticals; environmental biotechnology; and, industrial biotechnology and bioprocessing. BioAlberta activities are focused on advocacy, promotion and proactively facilitating the growth of Alberta's life sciences industry. The association provides attentive, proactive and timely services and programs to member organizations. Whether it is a cost savings of a purchasing program, a marketing campaign, a publication, an educational session, or an advocacy campaign, BioAlberta expands members' dollars and reach. More information is available at www.bioalberta.com.
About Ceapro Inc.
Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and "active ingredients" from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company's website at www.ceapro.com.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Investor and Media Contact:
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T (US): 908-938-1475
Source: Ceapro Inc.
Released November 26, 2014